1. The use of diazoxide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of autoimmune demyelinating disease of the central nervous system in a mammal, comprising manufacturing the aforementioned medicament in a daily dose of 0.075 ÷ 12.00 mg / mV day calculated as the free base diazoksida.2. Use according to claim 1, wherein the use of free form diazoxide in osnovaniya.3. Use according to claim 1, wherein the mammal is chelovekom.4. Use according to claim 1, wherein the disease is selected from the group consisting of multiple sclerosis, clinically isolated syndrome which causes swelling (tumor like), multiple sclerosis, acute multiple sclerosis Marburg, Balo concentric sclerosis, acute disseminated encephalomyelitis, postvaccinal encephalitis, post-infectious encephalomyelitis and neyrooptikomielit .5. Use according to claim 4, wherein the disease is selected from the group consisting of a clinically isolated syndrome which causes swelling (tumor like), multiple sclerosis, acute multiple sclerosis Marburg, Balo concentric sclerosis, acute disseminated encephalomyelitis, postvaccinal encephalitis, post-infectious encephalomyelitis and neyrooptikomielit.6. Use according to claim 4, wherein the disease is selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis and postvaccination entsefalit.7. Use according to claim 6, wherein the disease is diffuse skleroz.8. Use according to any one of p.p.1-7, wherein the medicament is prepared for oral vvedeniya.9. Use according to any one of p.p.1-7, wherein the medicament is prepared1. Применение диазоксида или его фармацевтически приемлемой соли при изготовлении лекарственного средства для лечения аутоиммунного демиелинизирующего заболевания центральной нервной системы у млекопитающего, включающее изготовление вышеуказанного лекарственного средства в суточной дозе 0,075÷12,00 мг/м2 в день в расчете на свободное основание диазоксида.2. Прим
